1-3 of 3
Silke Aigner
Close
Sort by
Journal Articles

BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib

Chantal Zuber, PhD, Benjamin Daelken, PhD, Silke Aigner, PhD, Thomas Haeder, PhD, Olga Ab, PhD, Kathleen Whiteman, PhD, Teru Hideshima, Robert J Lutz, PhD, Frank Osterroth, PhD, Christoph Uherek, PhD
Journal: Blood
Blood (2010) 116 (21): 3008.
https://doi.org/10.1182/blood.V116.21.3008.3008
Published: 2010
Journal Articles

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.

Hiroshi Ikeda, MD, PhD, Teru Hideshima, MD, PhD, Robert J. Lutz, Sonia Vallet, Samantha Pozzi, MD, Loredana Santo, Elisabetta Calabrese, Benjamin Dälken, Christoph Uherek, Silke Aigner, Frank Osterroth, Mariateresa Fultiniti, Yutaka Okawa, Giulia Perrone, Gullu Gorgun, Hiroshi Yasui, Diana Cristia, Noopur Raje, MD, Nikhil Munshi, MD, Paul Richardson, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 1716.
https://doi.org/10.1182/blood.V112.11.1716.1716
Published: 2008
Journal Articles

CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on Human Tumor Cells

Silke Aigner, Zev M. Sthoeger, Mina Fogel, Erich Weber, Jürg Zarn, Michael Ruppert, Yvonka Zeller, Dietmar Vestweber, Rolf Stahel, Marei Sammar, Peter Altevogt
Journal: Blood
Blood (1997) 89 (9): 3385–3395.
https://doi.org/10.1182/blood.V89.9.3385
Published: 1997